Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial

Article full text The full text of this article can be found here. Provide enhanced content for this article If you are an author of this publication and would like to provide additional enhanced content for your article then please contact [email protected]. The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content. Other enhanced features include, but are not limited to: • Slide decks • Videos and animations • Audio abstracts • Audio slides</p

Patient selection for the development cohort.

Patient selection for the development cohort.</p

Scoring system for predictive baseline characteristics.

<p>Scoring system for predictive baseline characteristics.</p

Multivariate logistic regression analysis.

ALT = alanine aminotransferase; ALT ratio = ALT divided by ULN for the local laboratory; ULN = upper limit of normal. aWald chi-square test for each regression coefficient; b Wald chi-square test for each variable</p

Rate of response in treatment-naive cirrhotic and noncirrhotic Caucasian and patients with HCV genotype 3 by baseline score.

<p>Patients with missing scores omitted (noncirrhotic; n = 48, cirrhotic; n = 11). ^a Patients with missing information on cirrhosis status were given the same score as no cirrhosis.</p

Relationship between alanine aminotransferase (ALT)/upper limit of normal (ULN) and sustained virologic response (SVR).

<p>Short vertical lines indicate the number of patients with SVR (black lines) and no SVR (grey lines). Open circles represent probability of SVR according to the GAM analysis. Closed circles represent empirical probability for midpoints of deciles. ALT/ULN = patients' ALT divided by the ULN for the local laboratory</p

Sustained virologic response and relapse rates in treatment-naive Caucasian patients with HCV genotype 3 by baseline prediction score.

<p>A) Development cohort; B) Validation cohort SVR = sustained virologic response 24 weeks post-treatment. ^a 73 patients did not have a score and were omitted; of these, 46 (63.0%) achieved SVR. ^b Patients with end-of-treatment response and sufficient follow-up.</p

Relationship between age and sustained virologic response (SVR).

<p>Short vertical lines indicate the number of patients with SVR (black lines) and no SVR (grey lines). Open circles represent probability of SVR according to the GAM analysis. Closed circles represent empirical probability for midpoints of deciles.</p

Patient selection for the validation cohort.

<p>Patient selection for the validation cohort.</p

Relationship between bodyweight and sustained virologic response (SVR).

<p>Short vertical lines indicate the number of patients with SVR (black lines) and no SVR (grey lines). Open circles represent probability of SVR according to the GAM analysis. Closed circles represent empirical probability for midpoints of deciles.</p